| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-3.32美元,归母净利润-6540万美元,同比去年增长73.77%
|
| 2024-03-26 |
详情>>
业绩披露：
2023年其他每股收益-122.75美元,归母净利润-16.31亿美元,同比去年增长-421.02%
|
| 2024-03-26 |
详情>>
业绩披露：
2023年年报每股收益-1.94美元,归母净利润-3820万美元,同比去年增长93.61%
|
| 2024-03-26 |
详情>>
业绩披露：
2021年年报每股收益-8.47美元,归母净利润-7.17亿美元,同比去年增长24.05%
|
| 2023-11-07 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-205.37美元,归母净利润-27.22亿美元,同比去年增长-680.81%
|
| 2023-08-28 |
复牌提示：
2023-08-28 03:51:28 停牌，复牌日期 2023-08-28 17:00:00
|
| 2023-08-09 |
详情>>
股本变动：
变动后总股本1328.92万股
变动原因 ▼▲
- 原因：
- 20230331-20230630
受限制股份的归属
|
| 2023-08-09 |
详情>>
业绩披露：
2023年中报每股收益-75.68美元,归母净利润-9.97亿美元,同比去年增长-1465.31%
|
| 2023-05-09 |
详情>>
业绩披露：
2023年一季报每股收益-18.93美元,归母净利润-2.49亿美元,同比去年增长-108.44%
|
| 2023-04-05 |
股东大会：
将于2023-05-16召开股东大会
会议内容 ▼▲
- 1.By separate resolutions, to elect as directors and to hold office, expiring at the end of the Company’s Annual General Meeting of Shareholders in 2024.
2.To hold an advisory non-binding vote to approve the re-appointment of Deloitte & Touche LLP as the independent auditors of the Company and, by binding vote, to authorize the Audit Committee of the Board of Directors (also referred to in this Proxy Statement as the “Board”) to set the independent auditors’ remuneration.
3.To hold an advisory non-binding vote to approve the Company’s executive compensation.
4.To authorize the Company and/or any subsidiary of the Company to make market purchases or overseas market purchases of Company shares.
5.To authorize the price range at which the Company can re-allot shares that it holds as treasury shares (Special Resolution).
6.To act on such other business as may properly come before the meeting or any adjournment thereof.
|
| 2023-03-03 |
详情>>
业绩披露：
2022年年报每股收益-45.41美元,归母净利润-5.98亿美元,同比去年增长16.63%
|
| 2023-02-28 |
财报披露：
美东时间 2023-02-28 盘前发布财报
|
| 2022-12-14 |
详情>>
内部人交易：
Tyndall Mark Anthony等共交易8笔
|
| 2022-11-08 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-26.41美元,归母净利润-3.49亿美元,同比去年增长32.10%
|
| 2022-08-11 |
详情>>
业绩披露：
2022年中报每股收益-4.83美元,归母净利润-6370万美元,同比去年增长74.49%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2020-04-02 |
股东大会：
将于2020-05-13召开股东大会
会议内容 ▼▲
- 1.By separate resolutions, to elect as directors for a period of one year, expiring at the end of the Company’s Annual General Meeting of Shareholders in 2021, the following individuals:(a)J. Martin Carroll,(b)Paul R. Carter,(c)David Y. Norton(d)Carlos V. Paya, M.D.,(e)JoAnn A. Reed,(f)Angus C. Russell,(g)Mark C. Trudeau,(h)Anne C. Whitaker,(i)Kneeland C. Youngblood, M.D.
2.To hold an advisory non-binding vote to approve the re-appointment of Deloitte & Touche LLP as the independent auditors of the Company and, by binding vote, to authorize the Audit Committee of the Board of Directors (also referred to in this Proxy Statement as the Board) to set the independent auditors’ remuneration.
3.To hold an advisory vote to approve the Company’s executive compensation
4.To hold an advisory vote relating to the frequency of future advisory votes to approve the Company’s executive compensation.
5.To approve the Board’s authority to issue shares
6.To authorize the Company and/or any subsidiary of the Company to make market purchases or overseas market purchases of Company shares.
7.To approve the change of name of the Company (Special Resolution).
8.To approve the waiver of pre-emption rights (Special Resolution).
9.To authorize the price range at which the Company can re-allot shares that it holds as treasury shares (Special Resolution).
10.To act on such other business as may properly come before the meeting or any adjournment thereof.
|
| 2019-04-03 |
股东大会：
将于2019-05-15召开股东大会
会议内容 ▼▲
- 1.By separate resolutions, to elect as directors for a period of one year, expiring at the end of the Company’s Annual General Meeting of Shareholders in 2020, the following individuals:
2.To hold an advisory non-binding vote to approve the re-appointment of Deloitte & Touche LLP as the independent auditors of the Company and, by binding vote, to authorize the Audit Committee of the Board of Directors (also referred to in this Proxy Statement as the Board) to set the independent auditors’ remuneration.
3.To hold an advisory vote to approve the Company’s executive compensation.
4.To approve the Board’s authority to issue shares.
5.To authorize the Company and/or any subsidiary of the Company to make market purchases or overseas market purchases of Company shares.
6.To approve the change of name of the Company (Special Resolution).
7.To approve the waiver of pre-emption rights (Special Resolution).
8.To authorize the price range at which the Company can re-allot shares that it holds as treasury shares (Special Resolution).
9.To consider shareholder proposals, numbered 9 to 11, if properly presented by the relevant shareholder proponents.
10.To act on such other business as may properly come before the meeting or any adjournment thereof.
|
| 2018-04-04 |
股东大会：
将于2018-05-16召开股东大会
会议内容 ▼▲
- 1.By separate resolutions, to elect as Directors for a period of one year, expiring at the end of the Company’s Annual General Meeting of Shareholders in 2019, the following individuals:
(a)David R. Carlucci(e)JoAnn A. Reed(i)Kneeland C. Youngblood, M.D.(b)J. Martin Carroll(f)Angus C. Russell(j)Joseph A. Zaccagnino(c)Paul R. Carter(g)Mark C. Trudeau (d)David Y. Norton(h)Anne C. Whitaker
2.To hold an advisory non-binding vote to approve the re-appointment of Deloitte & Touche LLP as the independent auditors of the Company and, by binding vote, to authorize the Audit Committee of the Board of Directors (also referred to in this Proxy Statement as the Board) to set the independent auditors’ remuneration.
3.To hold an advisory vote to approve the Company’s executive compensation.
4.To approve the Amended and Restated Mallinckrodt Pharmaceuticals Stock and Incentive Plan.
5.To approve the Board’s authority to issue shares.
6.To approve the waiver of pre-emption rights (Special Resolution).
7.To authorize the Company and/or any subsidiary of the Company to make market purchases or overseas market purchases of Company shares.
8.To authorize the price range at which the Company can re-allot shares that it holds as treasury shares (Special Resolution).
9.To act on such other business as may properly come before the meeting or any adjournment thereof.
|
| 2017-01-18 |
股东大会：
将于2017-03-01召开股东大会
会议内容 ▼▲
- 1.By separate resolutions, to elect as Directors for a period of one year, expiring at the end of the Company’s Annual General Meeting of Shareholders in 2018, the following individuals:
(a)Melvin D. Booth(e)JoAnn A. Reed(i)Kneeland C. Youngblood, M.D.
(b)David R. Carlucci(f)Angus C. Russell(j)Joseph A. Zaccagnino
(c)J. Martin Carroll(g)Virgil D. Thompson
(d)Diane H. Gulyas(h)Mark C. Trudeau
2.To hold an advisory non-binding vote to approve the re-appointment of Deloitte & Touche LLP as the independent auditors of the Company and, by binding vote, to authorize the Audit Committee of the Board of Directors to set the independent auditors’ remuneration.
3.To hold an advisory vote to approve the Company’s executive compensation.
4.To authorize the Company and/or any subsidiary of the Company to make market purchases or overseas market purchases of Company shares.
5.To authorize the price range at which the Company can re-allot shares that it holds as treasury shares (Special Resolution).
6.To approve the amendment of the Company's (a) Memorandum of Association to make certain administrative amendments and (b) Articles of Association to make certain administrative amendments (Special Resolutions).
7.To approve the reduction of Company capital (Special Resolution).
8.To act on such other business as may properly come before the meeting or any adjournment thereof.
|
| 2016-01-22 |
股东大会：
将于2016-03-16召开股东大会
会议内容 ▼▲
- 1.By separate resolutions, to elect as Directors for a period of one year, expiring at the end of the Company’s Annual General Meeting of Shareholders in 2017, the following individuals:
(a)Melvin D. Booth(e)Nancy S. Lurker(i)Mark C. Trudeau(b)David R. Carlucci
(f)JoAnn A. Reed(j)Kneeland C. Youngblood, M.D.(c)J. Martin Carroll(g)Angus C. Russell(k)Joseph A. Zaccagnino(d)Diane H. Gulyas(h)Virgil D. Thompson
2.To hold an advisory non-binding vote to approve the re-appointment of Deloitte & Touche LLP as the independent auditors of the Company and, by binding vote, to authorize the Audit Committee of the Board of Directors to set the auditors’ remuneration.
3.To hold an advisory vote to approve the Company’s executive compensation.
4.To approve the 2016 Mallinckrodt Pharmaceuticals Employee Stock Purchase Plan.
5.To authorize the Company and/or any subsidiary of the Company to make market purchases or overseas market purchases of Company shares.
6.To authorize the price range at which the Company can re-allot shares that it holds as treasury shares (Special Resolution).
7.To act on such other business as may properly come before the meeting or any adjournment thereof.
|
| 2015-01-23 |
股东大会：
将于2015-03-19召开股东大会
会议内容 ▼▲
- 1.By separate resolutions, to elect as Directors for a period of one year, expiring at the end of the Company’s Annual General Meeting of Shareholders in 2016, the following individuals:(a)Melvin D. Booth;(b) Don M. Bailey;(c) David R. Carlucci;(d) J. Martin Carroll;(e) Diane H. Gulyas;(f) Nancy S. Lurker;(g) JoAnn A. Reed;(h) Angus C. Russell;(i) Virgil D. Thompson;(j) Mark C. Trudeau;(k) Kneeland C. Youngblood, M.D.;(l) Joseph A. Zaccagnino.
2.To hold an advisory non-binding vote to approve the appointment of Deloitte & Touche LLP as the independent auditors of the Company and, by binding vote, to authorize the Audit Committee of the Board of Directors to set the auditors’ remuneration.
3.To hold an advisory vote to approve the Company’s executive compensation.
4.Approval of the Amended and Restated Mallinckrodt Pharmaceuticals Stock and Incentive Plan.
5.To authorize the Company and/or any subsidiary of the Company to make market purchases of Company shares.
6.To authorize the price range at which the Company can reissue shares that it holds as treasury shares. (Special Resolution)
7.To authorize the Board to determine whether to hold the 2016 annual general meeting of shareholders of Mallinckrodt at a location outside of Ireland.
8.To act on such other business as may properly come before the meeting or any adjournment thereof.
|
| 2014-01-24 |
股东大会：
将于2014-03-20召开股东大会
会议内容 ▼▲
- 1. By separate resolutions, to elect as Directors for a period of one year, expiring at the end of the Company’s Annual General Meeting of Shareholders in 2015, the following individuals:(a) Melvin D. Booth (b) David R. Carlucci (c) J. Martin Carroll (d) Diane H. Gulyas (e) Nancy S. Lurker (f) JoAnn A. Reed
(g) Mark C. Trudeau (h) Kneeland C. Youngblood, M.D. (i) Joseph A. Zaccagnino
2. To hold an advisory non-binding vote to approve the appointment of Deloitte & Touche LLP as the independent auditors of the Company and, by binding vote, to authorize the Audit Committee of the Board of Directors to set the auditors’ remuneration;
3. To hold an advisory vote to approve the Company’s executive compensation;
4. To hold an advisory vote relating to the frequency of future shareholder advisory votes to approve the Company’s executive compensation;
5. To authorize the Company and/or any subsidiary of the Company to make market purchases of Company shares;
6. To authorize the price range at which the Company can reissue shares that it holds as treasury shares. (Special Resolution);
7. To act on such other business as may properly come before the meeting or any adjournment thereof.
|